• Home
  • About
  • All Companies
    • Recent
    • Summary Lists
  • Contact

MoonLake Immunotherapeutics

  • May 11, 2021
  • New Biotech Startups

MoonLake Immunotherapeutics is a Swiss biopharmaceutical company leveraging single-domain antibody (Nanobody®) technology to develop medicines for immunologic diseases, including inflammatory skin and joint diseases.

Nanobodies® are proprietary therapeutic proteins based on single-domain antibody fragments, with the benefits of conventional antibodies but at 1/10th the size. MoonLake has licensed Merck KGaA’s phase 3-ready drug sonelokimab (M1095) (originally discovered by Ablynx), an IL-17A/IL-17F inhibitor with an albumin binding site, which has the potential to facilitate deep tissue penetration in the skin and joints.

MoonLake was founded in 2021 and plans to accelerate the development of Sonelokimab in multiple inflammatory diseases in dermatology and rheumatology driven by IL-17A and IL-17F. This group of IL-17A/F Inflammatory Diseases includes psoriatic arthritis, ankylosing spondylitis, and hidradenitis suppurativa. MoonLake says it plans to initiate multiple Phase 2 trials soon.

The company recently published Phase 2b data in The Lancet showing Sonelokimab totally clears skin in almost 6 out of 10 patients with moderate to severe psoriasis.

MoonLake aims to develop Sonelokimab in multiple indications through to commercialization, potentially in partnership with established biopharma companies.


Subscribe for alerts on new companies featured on Startups.Bio


May 24, 2022Aulos Bioscience
Aulos Bioscience aims to revolutionize cancer patient care through the development of pioneering Interleukin-2 therapeutics for the treatment of solid tumor cancers. Interleukin-2 or IL-2 …
May 18, 2022Code Bio
Code Bio is using its novel targeted non-viral delivery platform to develop genetic medicines for serious and life-threatening diseases such as Type 1 Diabetes and …
May 9, 2022Muna Therapeutics
Muna Therapeutics aims to preserve brain function and enhance resilience to neurodegenerative diseases.  The company engages in the discovery and development of novel therapies that …
April 27, 2022Glyphic Biotechnologies
Glyphic Biotechnologies is an MIT spin-out aiming to accelerate the critical but slow step of sequencing new proteins, potentially cutting drug development times down by …
April 24, 2022ImmuneID 
ImmuneID is a precision immunology company that has developed a genome-wide, high-throughput platform to provide an understanding of individual immune responses. ImmuneID's aiSPIRE platform screens billions of …
April 15, 2022Flare Therapeutics
Flare uses a “switch-site based drug discovery approach” to develop a pipeline of therapeutic programs that target pivotal cancer drivers such as transcription factor dysregulation …

Tags:

© Copyright 2022. Startups.Bio, powered by VentureRadar.